Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167–78.
Article
Google Scholar
Fantl J, Newman D, Colling J, DeLancey J, Keeys C, Loughery R, McDowell B, Norton P, Ouslander J, Schnelle J (1996) Urinary Incontinence in Adults: Acute and Chronic Management. Clinical Practice Guideline No. 2, 1996 Update (AHCPR Publication No. 96–0682). Rockville, MD: US Department of Health and Human Services. Public health service, Agency for health care policy and research.
Garnett S, Abrams P. The natural history of the overactive bladder and detrusor overactivity. A review of the evidence regarding the long-term outcome of the overactive bladder. J Urol. 2003;169(3):843–8.
Article
Google Scholar
Knutson T, Edlund C, Fall M, Dahlstrand C. BPH with coexisting overactive bladder dysfunction—an everyday urological dilemma. Neurourol Urodyn. 2001;20(3):237–47.
CAS
Article
Google Scholar
Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80. https://doi.org/10.1016/j.juro.2015.01.087.
Article
PubMed
Google Scholar
Coyne KS, Margolis MK, Kopp ZS, Kaplan SA. Racial differences in the prevalence of overactive bladder in the United States from the epidemiology of LUTS (EpiLUTS) study. Urology. 2012;79(1):95–101. https://doi.org/10.1016/j.urology.2011.09.010.
Article
PubMed
Google Scholar
Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, Milsom I. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101(11):1388–95. https://doi.org/10.1111/j.1464-410X.2008.07601.x.
Article
PubMed
Google Scholar
Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int. 2009;103(Suppl 3):4–11. https://doi.org/10.1111/j.1464-410X.2009.08371.x.
Article
PubMed
Google Scholar
Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97(1):96–100. https://doi.org/10.1111/j.1464-410X.2005.05889.x.
Article
PubMed
Google Scholar
Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–36. https://doi.org/10.1007/s00345-002-0301-4.
CAS
Article
PubMed
Google Scholar
Sexton CC, Coyne KS, Vats V, Kopp ZS, Irwin DE, Wagner TH. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–s107.
PubMed
Google Scholar
Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006;148(5):565–78. https://doi.org/10.1038/sj.bjp.0706780.
CAS
Article
PubMed
PubMed Central
Google Scholar
Kumar V, Templeman L, Chapple CR, Chess-Williams R. Recent developments in the management of detrusor overactivity. Curr Opin Urol. 2003;13(4):285–91.
Article
Google Scholar
Rai BP, Cody JD, Alhasso A, Stewart L (2012) Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews 12:CD003193. https://doi.org/10.1002/14651858.CD003193.pub4.
Wyndaele J-J. Fesoterodine: individualised treatment of urgency urinary incontinence across patient groups. Eur Urol Suppl. 2011;10(1):14–22.
CAS
Article
Google Scholar
Andersson KE. On the site and mechanism of action of beta3-adrenoceptor agonists in the bladder. International neurourology journal. 2017;21(1):6–11. https://doi.org/10.5213/inj.1734850.425.
Article
PubMed
PubMed Central
Google Scholar
Food and Drug Administration (2012) Myrbetriq (mirabegron) Full Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202611s000lbl.pdf Accessed on April 8, 2018.
Wagg AS, Foley S, Peters J, Nazir J, Kool-Houweling L, Scrine L (2017) Persistence and adherence with mirabegron vs antimuscarinics in overactive bladder: retrospective analysis of a UK general practice prescription database. Int J Clin Pract 71 (10). https://doi.org/10.1111/ijcp.12996.
Andersson K-E. Drugs for the overactive bladder: are there differences in persistence and compliance? Translational andrology and urology. 2017;6(3):597–601. https://doi.org/10.21037/tau.2017.03.90.
Article
PubMed
PubMed Central
Google Scholar
Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev. 2012;1:CD005429. https://doi.org/10.1002/14651858.CD005429.pub2.
Article
PubMed
Google Scholar
McDonagh MS, Jonas DE, Gartlehner G, Little A, Peterson K, Carson S, et al. Methods for the drug effectiveness review project. BMC Med Res Methodol. 2012;12:140.
Article
Google Scholar
Methods Guide for Effectiveness and Comparative Effectiveness Reviews (January 2014). Agency for Healthcare Research and Quality, Rockville, MD.
Coyne KS, Matza LS, Kopp Z, Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol. 2006;49(6):1079–86. https://doi.org/10.1016/j.eururo.2006.01.007.
Article
PubMed
Google Scholar
Coyne KS, Matza LS, Thompson CL, Kopp ZS, Khullar V. Determining the importance of change in the overactive bladder questionnaire. J Urol. 2006;176(2):627–32; discussion 632. https://doi.org/10.1016/j.juro.2006.03.088.
Article
PubMed
Google Scholar
Gotoh M, Homma Y, Yokoyama O, Nishizawa O. Responsiveness and minimal clinically important change in overactive bladder symptom score. Urology. 2011;78(4):768–73. https://doi.org/10.1016/j.urology.2011.06.020.
Article
PubMed
Google Scholar
Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000;320(7249):1574–7.
CAS
Article
Google Scholar
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
Article
Google Scholar
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.
Article
Google Scholar
Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol 67. 2015;(3):577–88. https://doi.org/10.1016/j.eururo.2014.02.012.
Astellas (2010) A randomized, double-blind, parallel group, placebo and active controlled, multicenter dose ranging study with the beta-3 agonist YM178 in patients with symptomatic overactive bladder (DRAGON).1–8.
Aziminekoo E, Ghanbari Z, Hashemi S, Nemati M, Haghollahi F, Shokuhi N. Oxybutynin and tolterodine in a trial for treatment of overactive bladder in Iranian women. Journal of Family and Reproductive Health. 2014;8(2):73–6.
PubMed
Google Scholar
Batista JE, Kolbl H, Herschorn S, Rechberger T, Cambronero J, Halaska M, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015;7(4):167–79.
CAS
Article
Google Scholar
But I, Goldstajn MS, Oreskovic S. Comparison of two selective muscarinic receptor antagonists (solifenacin and darifenacin) in women with overactive bladder—the SOLIDAR study. Coll Antropol. 2012;36(4):1347–53.
PubMed
Google Scholar
Chapple CR, Dvorak V, Radziszewski P, Van Kerrebroeck P, Wyndaele JJ, Bosman B, et al. A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2013;24(9):1447–58. https://doi.org/10.1007/s00192-013-2042-x.
Article
Google Scholar
Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder. Eur Urol. 2013;63(2):296–305. https://doi.org/10.1016/j.eururo.2012.10.048.
CAS
Article
PubMed
Google Scholar
Dede H, Dolen I, Dede FS, Sivaslioglu AA. What is the success of drug treatment in urge urinary incontinence? What should be measured? Arch Gynecol Obstet. 2013;287(3):511–8. https://doi.org/10.1007/s00404-012-2596-8.
CAS
Article
PubMed
Google Scholar
Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, Herschorn S, Saleem T, Huang M, Siddiqui E, Stolzel M, Herholdt C, MacDiarmid S, investigators Bs (2016) Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol 70 (1):136–145.
Drake MJ, MacDiarmid S, Chapple CR, Esen A, Athanasiou S, Cambronero Santos J, Mitcheson D, Herschorn S, Siddiqui E, Huang M, Stoelzel M (2017) Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). Int J Clin Pract 71 (5). https://doi.org/10.1111/ijcp.12944.
Ercan O, Kostu B, Bakacak M, Aytac-Tohma Y, Coskun B, Avci F, et al. Comparison of solifenacin and fesoterodine in treatment of overactive bladder. Saudi Med J. 2015;36(10):1181–5. https://doi.org/10.15537/smj.2015.10.12016.
Gratzke C, van Maanen R, Chapple C, Abrams P, Herschorn S, Robinson D, Ridder A, Stoelzel M, Paireddy A, Yoon SJ, Al-Shukri S, Rechberger T, Mueller ER. Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II). Eur Urol. 2018;74(4):501–509. https://doi.org/10.1016/j.eururo.2018.05.005.
Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562–75.
CAS
Article
Google Scholar
Herschorn S, Pommerville P, Stothers L, Egerdie B, Gajewski J, Carlson K, et al. Tolerability of solifenacin and oxybutynin immediate release in older (> 65 years) and younger (< 65 years) patients with overactive bladder: sub-analysis from a Canadian, randomized, double-blind study. Curr Med Res Opin. 2011;27(2):375–82. https://doi.org/10.1185/03007995.2010.541433.
CAS
Article
PubMed
Google Scholar
Herschorn S, Staskin D, Tu LM, Fialkov J, Walsh T, Gooch K, et al. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER). Health Qual Life Outcomes. 2018;16(1):69. https://doi.org/10.1186/s12955-018-0892-0.
Article
PubMed
PubMed Central
Google Scholar
Hsiao SM, Chang TC, Wu WY, Chen CH, Yu HJ, Lin HH. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res. 2011;37(8):1084–91. https://doi.org/10.1111/j.1447-0756.2010.01493.x.
CAS
Article
PubMed
Google Scholar
Jafarabadi M, Ghanbari Z, Hashemi S, Nemati M, Haghollahi F, Azimi Nekoo E. Prominent complaint: a guide to medical therapy of overactive bladder syndrome in older women. Acta Med Iran. 2015;53(2):125–8.
PubMed
Google Scholar
Jafarabadi M, Jafarabadi L, Shariat M, Rabie Salehi G, Haghollahi F, Rashidi BH. Considering the prominent complaint as a guide in medical therapy for overactive bladder syndrome in women over 45 years. J Obstet Gynaecol Res. 2015;41(1):120–6. https://doi.org/10.1111/jog.12483.
CAS
Article
PubMed
Google Scholar
Khullar V, Amarenco G, Angulo JC, Blauwet MB, Nazir J, Odeyemi IA, Hakimi Z. Patient-reported outcomes with the beta(3)-adrenoceptor agonist mirabegron in a phase III trial in patients with overactive bladder. Neurourol Urodyn. 2016;35(8):987–994
Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63(2):283–95. https://doi.org/10.1016/j.eururo.2012.10.016.
CAS
Article
PubMed
Google Scholar
Kinjo M, Sekiguchi Y, Yoshimura Y, Nutahara K. Long-term persistence with mirabegron versus solifenacin in women with overactive bladder: prospective, randomized trial. Low Urin Tract Symptoms. 2016;10(2):148–152. https://doi.org/10.1111/luts.12151.
Kosilov K, Loparev S, Ivanovskaya M, Kosilova L. A randomized, controlled trial of effectiveness and safety of management of OAB symptoms in elderly men and women with standard-dosed combination of solifenacin and mirabegron. Arch Gerontol Geriatr. 2015;61(2):212–6. https://doi.org/10.1016/j.archger.2015.06.006.
CAS
Article
PubMed
Google Scholar
Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, Kuroishi K (2015) Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn, vol 34. https://doi.org/10.1002/nau.22645.
Manjunatha R, Pundarikaksha HP, Hanumantharaju BK, Anusha SJ. A prospective, comparative study of the occurrence and severity of constipation with darifenacin and trospium in overactive bladder. J Clin Diagn Res. 2015;9(3):FC05–9.
PubMed
PubMed Central
Google Scholar
NCT00431041 (2010) Study to compare the safety and efficacy of solifenacin with oxybutynin for the treatment of overactive bladder (VECTOR). ClinicalTrials.gov.
NCT00688688 (2013) Study to test the long-term safety and efficacy of the beta-3 agonist mirabegron (YM178) in patients with symptoms of overactive bladder (TAURUS). ClinicalTrials.gov.
NCT00689104 (2013) Study to assess the efficacy and safety of the beta-3 agonist mirabegron (YM178) in patients with symptoms of overactive bladder (SCORPIO). ClinicalTrials.gov.
NCT00966004 (2010) A study to evaluate safety and efficacy of YM178 in patients with overactive bladder. ClinicalTrials.gov
NCT01043666 (2011) A study of YM178 in subjects with symptoms of overactive bladder. ClinicalTrials.gov
NCT01340027 (2015) A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin Succinate Alone and in combination for the treatment of overactive bladder (Symphony). ClinicalTrials.gov.
NCT01638000 (2015) A study to evaluate the efficacy and safety of mirabegron compared to solifenacin in patients with overactive bladder who were previously treated with another medicine but were not satisfied with that treatment (BEYOND). ClinicalTrials.gov.
NCT01908829 (2016) A trial comparing combination treatment (solifenacin plus mirabegron) with one treatment alone (Solifenacin) (BESIDE). ClinicalTrials.gov.
NCT01972841 (2017) This was a multinational study comparing the efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, or a mock treatment (placebo) in subjects with symptoms of overactive bladder (SYNERGY). ClinicalTrials.gov.
NCT02045862 (2018) A multinational study comparing the long-term efficacy and safety of two medicines, solifenacin succinate and mirabegron taken together, or separately, in subjects with symptoms of overactive bladder (SYNERGY II). ClinicalTrials.gov.
NCT02138747 (2018) A study to evaluate tolerability and participants’ preference between mirabegron and tolterodine extended release (ER) in participants with overactive bladder (OAB) (PREFER). ClinicalTrials.gov.
Rana M, Mobusher I. Comparison of side effects of tolterodine and solifenacinsucinate in patients with urinary incontinence. Pakistan Journal of Medical and Health Sciences. 2016;10(1):176–80.
Google Scholar
Robinson D, Kelleher C, Staskin D, Mueller ER, Falconer C, Wang J, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Hakimi Z, Herschorn S Patient-reported outcomes from SYNERGY, a randomized, double-blind, multicenter study evaluating combinations of mirabegron and solifenacin compared with monotherapy and placebo in OAB patients. Neurourol Urodyn. 2017;37(1):394–406. https://doi.org/10.1002/nau.23315.
Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Int Urogynecol J Pelvic Floor Dysfunct. 2018;29(2):273–83. https://doi.org/10.1007/s00192-017-3377-5.
Article
Google Scholar
Vecchioli Scaldazza C, Morosetti C. Comparison of therapeutic efficacy and urodynamic findings of solifenacin succinate versus mirabegron in women with overactive bladder syndrome: results of a randomized controlled study. Urol Int. 2016;97(3):325–9. https://doi.org/10.1159/000445808.
CAS
Article
PubMed
Google Scholar
White WB, Chapple C, Gratzke C, Herschorn S, Robinson D, Frankel J, Ridder A, Stoelzel M, Paireddy A, van Maanen R, Weber MA. Cardiovascular safety of the beta(3)-adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. J Clin Pharmacology. 2018;58(8):1084–1091. https://doi.org/10.1002/jcph.1107.
Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, et al. Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113(6):951–60. https://doi.org/10.1111/bju.12649.
CAS
Article
PubMed
Google Scholar
Diokno AC, Appell RA, Sand PK, Dmochowski RR, Gburek BM, Klimberg IW, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78(6):687–95.
CAS
Article
Google Scholar
Yeowell G, Smith P, Nazir J, Hakimi Z, Siddiqui E, Fatoye F. Real-world persistence and adherence to oral antimuscarinics and mirabegron in patients with overactive bladder (OAB): a systematic literature review. BMJ Open. 2018;8(11):e021889. https://doi.org/10.1136/bmjopen-2018-021889.
Article
PubMed
PubMed Central
Google Scholar
Akino H, Namiki M, Suzuki K, Fuse H, Kitagawa Y, Miyazawa K, et al. Factors influencing patient satisfaction with antimuscarinic treatment of overactive bladder syndrome: results of a real-life clinical study. Int J Urol. 2014;21(4):389–94. https://doi.org/10.1111/iju.12298.
CAS
Article
PubMed
Google Scholar
Heisen M, Baeten SA, Verheggen BG, Stoelzel M, Hakimi Z, Ridder A, et al. Patient and physician preferences for oral pharmacotherapy for overactive bladder: two discrete choice experiments. Curr Med Res Opin. 2016;32(4):787–96. https://doi.org/10.1185/03007995.2016.1142959.
CAS
Article
PubMed
Google Scholar
Maman K, Aballea S, Nazir J, Desroziers K, Neine ME, Siddiqui E, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014;65(4):755–65. https://doi.org/10.1016/j.eururo.2013.11.010.
CAS
Article
PubMed
Google Scholar
Drake MJ, Nitti VW, Ginsberg DA, Brucker BM, Hepp Z, McCool R, et al. Comparative assessment of the efficacy of onabotulinumtoxinA and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int. 2017;120(5):611–22.
CAS
Article
Google Scholar
Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of Mirabegron compared with Antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–33. https://doi.org/10.1016/j.eururo.2018.03.020.
CAS
Article
PubMed
Google Scholar
Obloza A, Kirby J, Yates D, Toozs-Hobson P. Indirect treatment comparison (ITC) of medical therapies for an overactive bladder. Neurourol Urodyn. 2017;36(7):1824–31. https://doi.org/10.1002/nau.23189.
Article
PubMed
Google Scholar
Chou R, Carson S, Chan BK. Gabapentin versus tricyclic antidepressants for diabetic neuropathy and post-herpetic neuralgia: discrepancies between direct and indirect meta-analyses of randomized controlled trials. J Gen Intern Med. 2009;24(2):178–88. https://doi.org/10.1007/s11606-008-0877-5.
Article
PubMed
Google Scholar
National Institute for Health and Care Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2012.
Google Scholar
Higgins J, Green S, (editors) (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration:Section 16.16.12. Available from www.handbook.cochrane.org
Shah S, Nitti VW. Defining efficacy in the treatment of overactive bladder syndrome. Reviews in urology. 2009;11(4):196–202.
PubMed
PubMed Central
Google Scholar